Vasogen, Inc. (VSGN) Updates Shareholders
Vasogen Inc. (VSGN) has announced the results from the company's phase III Clinical trials of the drug "Celacade". According to findings by Lancet, this drug was able to reduce the risk of death or cardiovascular hospitalizations by 39% when compared to patients receiving a placebo drug. Chris Waddick, President and CEO of Vasogen, stated, "We believe that the publication of the ACCLAIM results, in a journal renowned for the communication of high-quality peer-reviewed research from around the world, is indicative of the exceptional design and execution of the trial, as well as the important contribution of ACCLAIM in identifying the…